Scholarlink

Abstract <p>De novo expression of the mesenchymal protein vimentin in the cells expressing epithelial cytokeratins was quantified by double immunofluorescence staining of serous ovarian cancer samples (<i>n</i> = 56). The median value was shown to be 1.6 times higher (<i>p</i> = 0.006) in the group of resistant tumors compared with that of sensitive tumors (disease relapse after chemotherapy with platinum drugs and taxanes for ≤6 months and ≥12 months). Conclusions. The level of de novo vimentin expression is a predictor of the efficacy of platinum drugs and taxanes with the calculated specificity and sensitivity of the assay of more than 80% and the cutoff value of 42.5% for sensitive and resistant tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunofluorescence Assay of De Novo Vimentin Expression in Serous Ovarian Cancer Cells as a Potential Predictor of the Efficacy of Platinum-Based Drugs and Taxanes

  • 期刊论文

  • 发表日期：

    2026年2月1日

查看全文
  • T. A. Bogush,
  • A. N. Grishanina,
  • E. A. Bogush,
  • A. M. Scherbakov,
  • E. A. Ogurechnikova,
  • A. B. Ravcheeva,
  • E. M. Kapura-Brekhovskikh,
  • M. Ya. Melnikov

摘要

Abstract

De novo expression of the mesenchymal protein vimentin in the cells expressing epithelial cytokeratins was quantified by double immunofluorescence staining of serous ovarian cancer samples (n = 56). The median value was shown to be 1.6 times higher (p = 0.006) in the group of resistant tumors compared with that of sensitive tumors (disease relapse after chemotherapy with platinum drugs and taxanes for ≤6 months and ≥12 months). Conclusions. The level of de novo vimentin expression is a predictor of the efficacy of platinum drugs and taxanes with the calculated specificity and sensitivity of the assay of more than 80% and the cutoff value of 42.5% for sensitive and resistant tumors.